Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131262 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL18535303 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL6841285 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13191782 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL1738672 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL12374614 | 1.00 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL24672314 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL8815319 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13191781 | 0.85 | CA2 (0.35) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL24687709 | 0.83 | CA2 (0.35) | CA2CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3600273-A1 | CD73 INHIBITORS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2018183635-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-3262057-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-1539188-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | CA2 4688/4885CA1 4100/4885CA9 2498/4885 |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | CA2 1703/4885CA1 2714/4885CA9 1443/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | CA2 4481/4885CA1 3914/4885CA9 1870/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | CA2 3466/4885CA1 2420/4885CA9 2062/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | CA2 1414/4885CA1 3152/4885CA9 1388/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | CA2 1703/4885CA1 2714/4885CA9 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.